Portfolio News | September 22, 2008
NxStage Named Fastest Growing Company in Massachusetts
LAWRENCE, Mass., Sept. 22 /PRNewswire-FirstCall/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that for the second consecutive year it has been recognized as the Fastest Growing Company in Massachusetts by the Boston Business Journal.
NxStage’s Chief Executive Officer, Jeffrey H. Burbank, credits the Company’s strategic efforts to increase awareness of daily home hemodialysis therapy, patient adoption of the therapy, and the completion of its Medisystems acquisition as key drivers behind NxStage’s 188% revenue growth from 2006-2007.
“We are very pleased to be selected as the fastest growing company in Massachusetts for the second year in a row,” said Burbank. “Our strong growth and continued success validate the strength of our strategy to provide innovative products that deliver enhanced benefits to patients and providers across all three of our product markets.”
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end stage renal disease and acute kidney failure. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage’s System One and other products, changes in market adoption of home daily hemodialysis, and other factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations